Efforts aimed at assessing pharmacotherapy of pulmonary arterial hypertension (PHT) have largely focused on patients with primary PHT, PHT associated with selected connec tive tissue diseases, and various forms of hypoxic secondary PHT. Part I of this review discusses the value and limitations of a wide variety of vasodilator drugs, oxygen, and warfarin in the treatment of primary PHT with special reference to their effects on pulmonary and systemic hemodynamics, functional capacity, and survival.
Get full access to this article
View all access options for this article.
References
1.
Grossman W., Braunwald E.: Pulmonary hypertension. In: Heart Disease: A Textbook of Cardiovascular Disease, ed. 4, ed by Braunwald E. Philadelphia : W. B. Saunders Co, 1992, pp 790-818.
Packer M.: Vasodilator therapy for pulmonary hypertension: Limitations and hazards . Ann Intern Med103:258-270, 1985.
4.
Rich S., Brundage BH, Levy PS: The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation71:1191-1196, 1985.
5.
Fuster V., Steele PM, Edwards WD, et al: Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation70:580-587, 1874.
6.
Dresdale DT, Michtom RJ, Schultz M.: Recent studies in primary pulmonary hypertension including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med30:195-207, 1954.
Samet P., Bernstein WH: Loss of reactivity of the pulmonary vascular bed in primary pulmonary hypertension . Am Heart J66:197-199, 1963.
9.
Maseri A., Caldini P., Howard P., et al:Determinants of pulmonary vascular volume: Recruitment versus distensibility . Circ Res31:218-228, 1982.
10.
Wagenvoort CA, Wagenvoort N.: Primary pulmonary hypertension: A pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation42:1163-1184, 1970 .
11.
Patient Registry for the Characterization of Primary Pulmonary Hypertension: Primary pulmonary hypertension: A national prospective registry . Ann Intern Med107:216-223, 1987.
12.
Patient Registry for the Characterization of Primary Pulmonary Hypertension. Survival in patients with primary pulmonary hypertension. Ann Intern Medicine115:343-349, 1991.
13.
Dresdale DT , Schultz M., Michtom RJ: Primary pulmonary hypertension: Clinical and hemodynamic study. Am J Med11:686-705, 1951.
14.
Walcott G., Burchell HB, Brown ALJr: Primary pulmonary hypertension. Am J Med49:70-79, 1970.
15.
Rich S., Levy PS: Characteristics of surviving and non-surviving patients with primary pulmonary hypertension. Am J Med76:573-578, 1984.
Winters WLJr , Joseph RR, Learner N.: "Primary" pulmonary hypertension and Raynaud's phenomenon. Case report and review of the literature. Arch Intern Med114:821-830, 1964.
Elkayam U.: Vasodilator therapy in primary pulmonary hypertension. Chest79:253-254, 1981.
22.
Rich S., Martinez J., Lam W., et al: Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: Guidelines for determining a pulmonary vasodilator response . Am Heart J105:119-127, 1983.
23.
Wood P., Besterman EM, Towers MK, et al: The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis. Br Heart J19:279-286, 1957.
24.
Charms BL: Primary hypertension effect of unilateral pulmonary artery occlusion and infusion of acetylcholine. Am J Cardiol8:94-97, 1969.
25.
Samet P., Bernstein WH, Widrich J.: Intracardiac infusion of acetylcholine in primary pulmonary hypertension . Am Heart J60:433-439, 1960.
26.
Yucleoglu YZ , Dresdale DT, Valensi QJ, et al: Primary pulmonary hypertension with hoarseness and (fatal) hemophysis. Vasc Dis4:290-294, 1967.
27.
Rao Bns, Moller JH, Edwards JE: Primary pulmonary hypertension in a child: Response to pharmacologic agents . Circulation40:583-587, 1969.
28.
Harkis P.: Influence of acetylcholine on the pulmonary artery pressure. Br Heart J19:272-278, 1957.
29.
Marshall RJ, Helmholz HFJr, Shepard JT: Effects of acetylcholine on pulmonary vascular resistance in a patient with idiopathic pulmonary hypertension. Circulation20:391-395, 1959.
30.
Rudolph AM, Paul MH, Sommer LS, et al: Effects of tolazoline hydrochloride (priscoline) on circulatory dynamics in patients with pulmonary hypertension. Am Heart J55:424-432, 1958.
31.
Yu PN: Primary pulmonary hypertension: Report of six cases and review of the literature . Ann Intern Med90:772-777, 1979.
32.
Gardiner JM : The effects of "priscol" in pulmonary hypertension . Aust Ann Med3:59-63, 1961.
33.
Grover RF, Reeves JT, Blount SGJr: Tolazoline hydrochloride (priscoline): An effective pulmonary vasodilator . Am Heart J61:5-15, 1961.
34.
Ruskin JN, Hutter AMJr: Primary pulmonary hypertension treated with oral phentolamine. Ann Intern Med90:772-774, 1979.
35.
Cohen ML, Kronzon I.: Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension . Ann Intern Med95:591-592, 1985.
36.
Levine TB, Rose T., Kane M., et al: Treatment of primary pulmonary hypertension by alpha adrenergic blockade [Abstract]. Circulation62:(suppl III):111-126, 1980.
37.
Shettigar UR , Hultgren HN, Specter M., et al: Primary pulmonary hypertension: Favorable effect of isoproterenol. N Engl J Med295:1414-1415, 1976.
38.
Pietro DA, LaBresh KA, Shulman RM, et al: Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol. N Engl J Med310:1032-1034, 1976.
39.
Lupi-Herrera E., Bialostozsky D., Sobrino A.: The role of isoproterenol in pulmonary artery hypertension of unknown etiology (primary): Short- and long-term evaluation . Chest79:792-796, 1991.
40.
Daoud FS, Reeves JT, Kelly DB: Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension . Am J Cardiol42:817-822, 1978.
41.
Elkayam U., Frishman WH, Yoran C., et al: Unfavorable hemodynamic and clinical effects of isoproterenol in primary pulmonary hypertension. Cardiovasc Med3:1177-1180, 1978.
42.
Person B., Proctor RG: Primary pulmonary hypertension: Responses to indomethacin, terbutaline and isoproterenol. Chest76:601-603, 1979.
43.
Rubin LJ, Peter RH: Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med302:69-73, 1980.
44.
Groves BH, Rubin LJ, Reeves JT, et al: Comparative hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension [Abstract]. Circulation64(suppl IV):297, 1980.
45.
Rich S., Ganz R., Levy PS: Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertensionCirculation64 (suppl IV):297, 1980.
46.
Lupi-Herrera E., Sandoval J., Sloane M., et al: The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause. Circulation65:645-650, 1982.
47.
Rubin LJ, Handel F., Peter RH: The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure. Circulation65:1369-1373, 1982.
48.
Rozkovec A. , Stradling J., Minty K., et al: Hydralazine in pulmonary hypertension . N Engl J Med307:1214-1215, 1982 .
49.
Fisher J., Borer JS, Moses JW, et al: Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension. Am J Cardiol54:646-650, 1984.
50.
Kronzon I., Cohen M., Winer HE: Adverse effect of hydralazine in patients with primary pulmonary hypertension . JAMA247:3112-3114, 1982 .
51.
Packer M., Greenberg B., Massie B., et al: Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med306:1326-1331, 1982.
52.
Wang Sws, Pohl JE, Rowlands DJ, et al: Diazoxide in treatment of primary pulmonary hypertension. Br Heart J40:572-574, 1978.
53.
Honey M., Cotter L., Davies N., et al: Clinical and hemodynamic effects of diazoxide in primary pulmonary hypertension. Br Heart J40:572-574, 1978.
54.
Rubino JM, Schroeder JS: Diazoxide in treatment of primary pulmonary hypertension [Letter] . Br Heart J42:362-363, 1979.
55.
Klinke WP, Gilbert JA: Diazoxide in primary pulmonary hypertension. N Engl J Med302:91-92, 1980.
56.
Hall DR, Petch MC: Remission of primary pulmonary hypertension during treatment with diazoxide . Br Med J282:1118, 1981.
57.
Buch J., Wennevold A.: Hazards of diazoxide in pulmonary hypertension. Br Heart J46:401-403, 1981.
58.
Pearl RG, Rosenthal MH, Schroeder JS, et al: Acute hemodynamic effects of nitroglycerin in pulmonary hypertension . Ann Intern Med99:9-13, 1983.
59.
Hermiller JB , Bambach D., Thompson MJ, et al: Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. Ann Intern Med97:480-489, 1982.
60.
Leier CV, Bambach D., Nelson S., et al: Captopril in primary pulmonary hypertension. Circulation67:155-161,1983.
61.
Ikram H., Maslowski AH, Nicholls MG, et al: Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. Br Heart J48:541-545, 1982.
62.
Kokubu T., Kazatani Y., Hamada M., et al: Is captopril effective in primary pulmonary hypertension?Jpn Circ J46:1095-1097, 1982 .
63.
Poderoso JJ, Biancolini CA, Del Bosco CG, et al: Captopril versus hydralazine in primary pulmonary hypertension . J Clin Pharmacol23:563-566, 1982.
64.
Rubin LJ, Nicod P., Hillis LD, et al: Treatment of primary pulmonary hypertension with nifedipine: A hemodynamic and scintigraphic evaluation. Ann Intern Med99:433-438, 1983.
65.
Olivari MT, Levine TB, Weir EK, et al: Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension. Chest86:14-19, 1984.
66.
Saito D., Haraoka S., Yoshida H., et al: Primary pulmonary hypertension improved by long-term oral administration of nifedipine. Am Heart J105:1041-1042, 1983.
67.
DeFeyter PJ , Kerkkamp Hjj, deJong JP: Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am Heart J105:333-334, 1983.
68.
Wise JR: Nifedipine in the treatment of primary pulmonary hypertension. Am Heart J105:693-694, 1983.
69.
Camerini F. , Alberti E., Klugmann S., et al: Primary pulmonary hypertension: Effects of nifedipine. Br Heart J44:352-356, 1980.
70.
Douglas JSJr : Hemodynamic effects of nifedipine in primary pulmonary hypertension. J Am Coll Cardiol2:174-179, 1983.
71.
Melot C., Naeije R., Mols P., et al: Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension. Chest83:203-207, 1983.
72.
Ribeiro PA, Sivanandan V., Sharkh A., et al: Decrease in pulmonary artery pressure with slow release nifedipine in Saudi patients with primary pulmonary hypertension. Rev Post Cardiol10:413-418, 1991.
73.
Musante R., DiDonato M.: Long-term favourable effect of nifedipine in primary pulmonary hypertension. Report of a case with hemodynamic evaluation after 3 and after 16 months and with clinical follow-up during 36 months. G Ital Cardiol15:1110-1112, 1985.
74.
Lunde P., Rasmussen K.: Long-term beneficial effect of nifedipine in primary pulmonary hypertension . Am Heart J108:415-416,1984.
75.
Arnman K., Ryden L., Smedgard P., et al: Felodipine in primary pulmonary hypertension: Report of two cases. Acta Med Scand215:175-180, 1984.
76.
Packer M., Medina N., Medina M.: Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease . J Am Coll Cardiol4:890-901, 1984.
77.
Aromatonio GJ, Uretsky BF, Reddy PS: Hypotension and sinus arrest with nifedipine in pulmonary hypertension. Chest87:265-267, 1985.
78.
Wood BA, Tortoledo F., Luck JC, et al: Rapid attenuation of response to nifedipine in primary pulmonary hypertension. Chest82:793-794, 1982.
79.
Farber HW, Karlinsky JB, Faling LJ: Fatal outcome following nifedipine for primary pulmonary hypertension . Chest83:708-709, 1983.
80.
Batra AK, Segall PH, Ahmed T.: Pulmonary edema with nifedipine in primary pulmonary hypertension . Respiration47:161-163, 1985.
81.
Kambara H., Fujimoto K., Wakabayashi A., et al: Primary pulmonary hypertension: Beneficial therapy with diltiazem . Am Heart J101:230-231, 1981.
82.
Packer M., Medina N., Yushak M., et al: Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J52: 106-111, 1984.
83.
Landmark K. , Refsum AM, Simonsen S., et al: Verapamil and pulmonary hypertension . Acta Med Scand204:299-302, 1978.
84.
Rich S., Kauffman E.: High-dose titration of calcium channel blocking agents for primary pulmonary hypertension: Guidelines for short-term drug testing. J Am Coll Cardiol18:1323-1327, 1991 .
85.
Rich S., Brundage BH: High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation76:135-141, 1987.
86.
Inbar S., Schrader BJ, Kauffman E., et al: Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol21:413-418, 1993.
87.
Rubin LJ, Mendoza J., Hood M., et al: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. AmIntern Med112:485-491, 1990.
88.
Higenbottam T., Wheeldon D., Wells F., et al: Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet1:1046-1047, 1984 .
89.
Kreiner G., Siostrzonek P., Heinz G., et al: Drug testing in patients with pulmonary hypertension of unknown cause. Eur Heart J13:776-780, 1991.
90.
Scott DP, Higenbottam T., Wallwork J.: The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pract44:231-234, 1990.
91.
Palevsky HI , Long W., Crow J., et al: Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation82:2016-2018, 1990.
92.
Jones K. Higenbottam T, Wallwork J.: Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest96:784-789, 1989.
93.
Long WA, Rubin LJ: Prostacyclin and PGE, treatment of pulmonary hypertension. Am Rev Respir Dis136:773-776, 1987.
94.
Rich S., Kaufmann E., Levy PS: The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med327:76-81, 1992.
